what are the negative effects of bpc 157 BPC-157: Tendon Repair and More Potential Side Effects of BPC-157

Novo Nordisk filed a New Drug Application for the CagriSema combination (cagrilintide 2.4 mg + semaglutide 2.4 mg) in December 2025, with an FDA decision anticipated in late 2026

The peptide's actin-sequestering activity enables the rapid cytoskeletal reorganization required for keratinocyte migration and fibroblast movement into wound sites, with studies showing 2-3 fold increases in migration rates and improved directional persistence compared to untreated controls

Human diabetic-ulcer study of topical glycyl-L-histidyl-L-lysine copper

It also inhibits matrix metalloproteinases (MMP-2 and MMP-9), the enzymes that break down collagen in damaged vein walls